BCL2-targeting therapies create impressive responses in CLL, where the bulk of the disease is circulating in the peripheral blood, however lymph-node mediated treatment resistance has been implicated in the inability to cure CLL [59]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.